A Biopharma M&A Bonanza In 2022? Analysts Pick Top Targets And Likely Buyers

Big Pharma Will Have $530bn To Spend

As big pharma company cash piles grow and biotech share prices plummet, a resurgence in mergers and acquisitions looks imminent.

Pfizer
Pfizer's COVID-19 vaccine windfall will help fuel its M&A strategy over the next 5 years. • Source: Alamy

After a relatively quiet 2021, sector analysts agree that 2022 looks set for a major upturn in merger activity – and not least because the 18 biggest pharma players will have amassed around $538bn to spend by the end of the year.

That was the calculation made by Jeffrey Porges, senior analyst at SVB Leerink in a note in early December 2021,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.